托法西提尼布用于治疗慢性囊炎:一个试点研究
Djuna C de Jong1, Rogier Goetgebuer1, Bart L M Müskens1
1Department of Gastroenterology and Hepatology, Amsterdam UMC, Amsterdam, The Netherlands.
United European gastroenterology journal
|February 3, 2025
概括
托法西提尼布在治疗耐火性囊炎方面表现出有效性,31%的性结肠炎患者在8周后实现了临床缓解. 虽然症状有所改善,但没有观察到内镜和组织学愈合,这表明可能需要更长时间的治疗.
科学领域:
- 胃肠病学 胃肠病学
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
背景情况:
- 高达15%的性结肠炎患者患有乳腺囊,患有慢性或抗生素耐药性囊.
- 这种情况显著影响生活质量,治疗选择有限.
研究的目的:
- 评估托法西提尼布在患有慢性或抗生素耐药性囊炎的患者的疗效和安全性.
- 评估托法西提尼布对临床,生化,内镜和组织学疾病活动的影响.
主要方法:
- 一项前性单一中心研究包括成人性结肠炎患者,这些患者患有耐火性皮炎 (皮炎疾病活动指数 (PDAI) ≥7).
- 患者接受托法西提尼布10毫克每天两次,持续8周.
- 疾病活性在基线和第8周被评估,临床缓解被定义为PDAI<7和≥3个点的基线减少.
主要成果:
- 31% (4/13) 的患者在8周后实现了PDAI定义的临床缓解.
- 54% (7/13) 的患者取得了临床反应.
- 总PDAI和临床子评分的显著减少被观察到,但内镜和组织学评分没有显著变化.
结论:
- 托法西替尼在耐火性囊炎的试点研究中显示出临床疗效,在31%的患者中实现了缓解.
- 8周的治疗时间可能不足以治愈粘膜,这是内镜和组织学得分不变的证据.
- 需要进行更长的治疗时间的进一步研究,以评估托法西提尼布在囊中的全部治疗潜力.
相关概念视频
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
114
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
114
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
141
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
141
01:21Inflammatory Bowel Disease V: Surgical Management
103
Surgical interventions for inflammatory bowel disease (IBD), which includes ulcerative colitis and Crohn's disease, are essential in managing symptoms and addressing complications. The selection of surgical procedures is contingent upon the specific conditions and complications that stem from these illnesses.
Here are some common surgical interventions for IBD:
Here are some common surgical interventions for IBD:
103
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
95
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
95
01:29Drugs for Treatment of Ulcerative Colitis in IBD
118
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
118
01:29Inflammatory Bowel Disease IV: Pharmacological Management
100
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
100